| Name | Title | Contact Details |
|---|
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders.
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Visit our technical products: omniab.com, captisol.com, vernalis.com and ltptechnology.com.
Canadian Bacterial Diseases Network (CBDN) is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Carterra, formerly Wasatch Microfluidics, develops high throughput surface plasmon resonance array-based platforms for biomolecular interaction analysis.
Novaseek is transforming how biomedical researchers access real-world hospital patient data and human biospecimens. Researchers rely on Novaseek to plan projects, and procure high quality biospecimens and clinical data needed to power discovery. Increasing productivity and de-risking projects across R&D enterprise begins with NovaSeek!